Imfinzi 120 mg/2.4 mL injection Images
Generic Name: durvalumab
This medication has been identified as Imfinzi 120 mg/2.4 mL injection. It is supplied by AstraZeneca.
Imfinzi is used in the treatment of Small Cell Lung Cancer; Non Small Cell Lung Cancer; Biliary Tract Tumor; Hepatocellular Carcinoma; Endometrial Cancer and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Imfinzi 120 mg/2.4 mL injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Imfinzi
- Generic Name
- durvalumab
- Strength
- 120 mg/2.4 mL injection
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- AstraZeneca
- National Drug Code (NDC)
- 00310-4500
More about Imfinzi (durvalumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (6)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.